share_log

Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $13

Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $13

Canaccord Genuity維持對Passage Bio的買入,將目標股價下調至13美元
Benzinga ·  05/15 21:34

Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $14 to $13.

Canaccord Genuity分析師惠特尼·伊傑姆維持Passage Bio(納斯達克股票代碼:PASG)的買入並將目標股價從14美元下調至13美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論